Lobbes H, Mahévas M, Alviset S, et al. - This study was sought to define the clinical and biological course, management, and response to treatment in Systemic Lupus Erythematosus (SLE)-associated Pure Red Cell Aplasia (PRCA). Between 2006 and 2018, a Nationwide multicentre retrospective cohort study was conducted including 24 patients (20 women) with a diagnosis of PRCA supported by bone-marrow examination and SLE or biologic manifestations of SLE after ruling out parvovirus B19 infection. It has been observed that SLE-associated PRCA is a severe condition. The data demonstrate that repeated red-blood-cell transfusions and several lines of immunosuppressant therapy are mostly required with a high risk of severe infectious events and iron overload. The best therapeutic strategy remains to be determined, despite sustained response for PRCA and SLE obtained in most patients.